WO2008012952A1 - Composition permettant de stimuler le métabolisme - Google Patents

Composition permettant de stimuler le métabolisme Download PDF

Info

Publication number
WO2008012952A1
WO2008012952A1 PCT/JP2007/000804 JP2007000804W WO2008012952A1 WO 2008012952 A1 WO2008012952 A1 WO 2008012952A1 JP 2007000804 W JP2007000804 W JP 2007000804W WO 2008012952 A1 WO2008012952 A1 WO 2008012952A1
Authority
WO
WIPO (PCT)
Prior art keywords
theanine
metabolism
fatigue
promoting
composition
Prior art date
Application number
PCT/JP2007/000804
Other languages
English (en)
Japanese (ja)
Inventor
Yoshitake Baba
Akihiro Abe
Ayumu Nozawa
Yuko Sagesaka
Takami Kakuda
Noritaka Okamura
Shojiro Tsukamoto
Taizo Kubo
Original Assignee
Ito En, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2006205967A external-priority patent/JP2008031080A/ja
Priority claimed from JP2006253686A external-priority patent/JP2008074733A/ja
Priority claimed from JP2006287105A external-priority patent/JP4709120B2/ja
Application filed by Ito En, Ltd. filed Critical Ito En, Ltd.
Publication of WO2008012952A1 publication Critical patent/WO2008012952A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to a metabolism-promoting composition containing theanine as an active ingredient, and more particularly to a metabolism-promoting composition characterized in that a metabolism-promoting action is produced by the fat utilization promoting action of theanine.
  • the present invention has the effect of promoting metabolism, improving endurance, promoting growth hormone secretion, increasing blood glucose level, fat burning, reducing fatigue during aerobic exercise, increasing anaerobic metabolic threshold, reducing blood lactate accumulation, anti-fatigue It is related with the metabolism promotion composition characterized by being, and the food / beverage which mix
  • the present invention relates to a method for promoting metabolism characterized by orally ingesting such a composition or food or drink.
  • Metabolism generally refers to a chemical reaction in a living body, and obtains energy by synthesizing a substance taken from outside the body into another substance.
  • energy metabolism primary metabolism
  • secondary metabolism secondary metabolism
  • drug metabolism etc.
  • Metabolism is known to involve processes such as anabolism and catabolism, and is involved in various actions in vivo.
  • Energy metabolism is also called central metabolism or primary metabolism. Energy metabolism involves both catabolic and catabolic reactions related to sugars, amino acids and fatty acids. On the other hand, secondary metabolism is related to the production of substances that are not involved in the central metabolic system. Drug metabolism (foreign substance metabolism) involves detoxification and detoxification of in vitro substances such as poisons and drugs. In the present invention, metabolism refers to energy metabolism or secondary metabolism, and does not include drug metabolism (foreign substance metabolism).
  • Such fatigue functions as an alarm for protecting the body and mind from excessive abuse, and is an in-vivo mechanism indispensable for maintaining a living body.
  • body fatigue functions as a vital defense system that prevents chronic fatigue and overwork death.
  • the brain senses that the body is impossible, the information is transmitted to the brain stem class body, from the brain stem class body to the hypothalamus, which is the center of the autonomic nervous system, as well as instincts such as appetite and sexual desire. It is transmitted to the limbic system that controls emotions, and further transmitted to the cerebral cortex that controls movement and the five senses, where information is analyzed and judged, and the command is transferred from the central nervous system to the autonomic nervous system, immune system, and endocrine system.
  • the information is transmitted and brings about physical changes.
  • the muscles are overworked with sports, the information is transmitted from the muscles to the brain, and the information is transmitted from the muscles to the brain, causing a feeling of fatigue, and causing muscle pain in the limbs.
  • compositions for example, isoflavones derived from soybeans (Patent Document 1), kabushinoids derived from pepper (Patent Document 2), guava leaf extract (Patent Document 3), grapes Origin of resveratrol (Patent Document 4) and the like are already known.
  • Patent Document 5 a nutrient that serves as an energy source
  • Patent Document 6 a feeling of fatigue due to the excitement effect
  • the present invention uses theanine as an active ingredient.
  • theanine has a relaxing effect (Patent Document 7) and a mental fatigue recovery effect (Patent Document 8). It is also known that theanine recovers fatigue associated with decreased blood flow (Patent Document 9).
  • Patent Document 7 a relaxing effect
  • Patent Document 8 a mental fatigue recovery effect
  • Patent Document 9 theanine recovers fatigue associated with decreased blood flow
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2 0202 _ 2 0 3 0 4
  • Patent Document 2 Japanese Patent Laid-Open No. 2 0 0 4 _ 1 4 9 4 9 4
  • Patent Document 3 Japanese Patent Laid-Open No. 2 0 0 5 _ 1 3 0 0 6
  • Patent Document 4 Japanese Laid-Open Patent Publication No. 2 0 0 7 _ 1 4 5 8 0 9
  • Patent Document 5 Japanese Patent Laid-Open No. 2 0 0 5 _ 0 9 7 1 6 1
  • Patent Document 6 Japanese Patent Laid-Open No. 09-9-0 5 9 1 6 1
  • Patent Document 7 Japanese Patent Laid-Open No. 2 0 0 2 _ 3 7 0 9 7 9
  • Patent Document 8 Japanese Patent Laid-Open No. 2 0 0 5 _ 1 8 7 3 4 4
  • Patent Document 9 Japanese Patent Laid-Open No. 2 0 0 1 _ 3 1 6 2 5 6
  • Non-patent document 1 Separate volume ⁇ History of medicine, science of fatigue, 2 0 0 1
  • An object of the present invention is to provide a highly safe energy metabolism promoting composition, in particular a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food or drink containing the metabolism promoting composition,
  • An object of the present invention is to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition and food and drink.
  • theanine has an energy metabolism promoting action, particularly an energy metabolism promoting action by a lipid utilization promoting action, and has completed the present invention.
  • Theanine also helps to improve endurance, promote growth hormone secretion, increase blood sugar levels, burn fat, reduce fatigue during aerobic exercise, increase anaerobic metabolic threshold, reduce blood lactate accumulation, and anti-fatigue. As a result, the present invention has been completed.
  • a metabolism promoting composition comprising theanine as an active ingredient
  • Metabolism-promoting action improves endurance, promotes growth hormone secretion, increases blood glucose levels, fat burning, reduces fatigue during aerobic exercise, increases anaerobic metabolic threshold, blood lactate accumulation
  • the metabolism promoting composition according to the above (1) or (2) characterized in that it is selected from the group consisting of reducing fatigue and anti-fatigue,
  • a method for promoting metabolism comprising orally ingesting the composition for promoting metabolism according to any one of (1) to (6) above,
  • Metabolism promoting action from lipid utilization promotion, growth hormone secretion promotion, blood sugar level increase, fat burning, fatigue reduction during aerobic exercise, anaerobic metabolic threshold increase, blood lactate accumulation reduction, anti-fatigue The method of promoting metabolism according to (7) above, wherein the method is one or more selected from the group consisting of:
  • a highly safe energy metabolism promoting composition particularly a metabolism promoting composition in which energy metabolism is promoted by a lipid utilization promoting action, a food and drink containing the metabolism promoting composition, It is possible to provide a method for promoting metabolism by orally ingesting such a metabolism promoting composition or food and drink.
  • the metabolism promoting composition of the present invention can be prepared by incorporating theanine as an active ingredient. These compositions can be incorporated into foods and beverages. Such metabolism promoting compositions and foods and drinks containing the same can be prepared by adding theanine. However, compositions containing theanine, plant extracts, foods and drinks and other theanine-containing substances It can also be prepared by blending.
  • Theanine is a derivative of glutamic acid contained in green tea and the like.
  • L-glutamic acid ethylamide L-theanine
  • L-glutamic acid __ methyl amide D-glutamic acid __
  • Derivatives containing L- or D-glutamic acid mono-alkyl amides, L- or D-glutamic acid _ -alkyl amides in the basic structure eg L-amino acid (D-theanine), D-glutamic acid _ _methyl amide, etc.
  • D-glutamic acid a glycoside of ⁇ _alkyl amide, etc.
  • a mixture of one or more compounds selected from the group consisting of two or more compounds can be used.
  • L-theanine is not only obtainable from natural products, but is also recognized as a food additive, and is particularly preferred from the standpoint of availability and safety.
  • Theanine can be produced by various known methods. For example, it can be biosynthesized by a culture method of plants or microorganisms, extracted from tea leaves, fermented or chemically synthesized. Specifically, JP-A-05-068578 (paragraphs [0006]-[0021]), JP-A-5-328986 (paragraphs [0008]-[0027]), JP-A-09-263573 (paragraphs [0009]-[0029]).
  • theanine can be used alone as an active ingredient of the metabolism-promoting composition of the present invention, but can also be used by mixing with other components.
  • Theanine can also be used as a lysate in purified products, crude products, tea extract extracts, purified water or physiological saline.
  • Metabolism in the present invention generally means a chemical reaction in a living body, and refers to synthesizing another substance or obtaining energy from a substance taken from outside the body.
  • metabolism promotion refers to promotion of energy metabolism and does not include drug metabolism.
  • energy metabolism energy consumed by moving the body
  • energy consumed without moving the body and doing nothing basic metabolism.
  • the promotion of metabolism means that the promotion of metabolism is promoted by promoting the utilization of lipids of theanine which is an active ingredient.
  • improve endurance means improving endurance and suppressing fatigue in a broad sense of exercise, such as work that requires endurance and labor that requires repeated muscle work. It has the effect
  • the metabolism promoting composition in the present invention is a composition containing theanine as an active ingredient and having such an action.
  • reducing fatigue during aerobic exercise means exercise that requires endurance, such as marathon, swimming, and air mouth bicus, and further work in daily life, such as oxygen consumption in the muscles and the cardiopulmonary system. This means that the oxygen supply by the body is in an equilibrium state and has the action of reducing physical fatigue that occurs when performing so-called aerobic exercise.
  • Fatigue is generally broadly divided into physical fatigue and mental fatigue.
  • the composition of the present invention reduces physical fatigue caused by aerobic exercise, and is directly applied only to spiritual fatigue. It does not work. However, in the case of both physical fatigue and mental fatigue, it is necessary to administer the metabolism promoting composition of the present invention. Needless to say, physical fatigue can be reduced.
  • an increase in the anaerobic metabolic threshold means an increase in the value of oxygen intake at the time when lactic acid begins to accumulate in the blood in the body.
  • Lactic acid is used as a source of energy for skeletal muscle and is therefore an important recovery factor during fatigue.
  • its importance has been pointed out in the brain and heart ("Separate volume ⁇ History of medicine: Fatigue chemistry", p. 14, p. 205).
  • excessive accumulation of lactic acid in the muscle causes performance degradation by reducing muscle activity. Therefore, suppressing the accumulation of lactic acid in the muscle is important in preventing fatigue.
  • Anaerobic threshold metabolism is defined as “the value of oxygen intake at the time when lactate begins to accumulate in the blood” (“Introduction to Exercise Testing”) 1 48, 2001).
  • the anaerobic threshold metabolic value was originally proposed by Wasserman, and is currently used as a standard in exercise testing combined with breath gas analysis.
  • the metabolism promoting composition in the present invention refers to a composition containing theanine as an active ingredient and having such an action.
  • blood lactate accumulation reduction refers to an action of suppressing blood lactate accumulation, and such blood lactate accumulation reduction also includes an action of reducing blood lactate.
  • lactic acid is considered to be a factor for fatigue recovery of muscles and the like, and the efficient use of lactic acid is desirable from the viewpoint of recovery from fatigue. If this accumulation of lactic acid is suppressed, it is possible to suppress muscle activity decline and exercise more intensely. Can do.
  • growth hormone refers to a hormone secreted from GH-secreting cells in the anterior pituitary gland under the action of growth hormone-releasing hormone (GHRH) secreted from the hypothalamus.
  • GHRH growth hormone-releasing hormone
  • Growth hormone is involved in the growth of the body and controls all metabolic mechanisms in the body, such as protein synthesis, nitrogen balance, carbohydrate metabolism, fat metabolism, and calcium homeostasis.
  • Carbohydrate metabolism refers to the regulation of blood sugar levels. An excessive increase in blood glucose level is not preferable because it may cause diseases such as hyperglycemia and diabetes.
  • the metabolism-promoting progenitor composition refers to a substance that promotes the secretion of growth hormone in vivo.
  • the blood glucose level refers to the concentration of glucose in the blood.
  • the blood glucose level is adjusted to a normal value within a very narrow range by the action of insulin that lowers blood sugar and the action of glucagon that raises blood sugar under normal conditions.
  • glucose passes through the GLUT 2 or GLUT 1 transporter; it flows into S cells.
  • glucose is converted to glucose 6-phosphate by the action of glucokinase, calcium ions flow into the cell and insulin is released.
  • the fasting blood glucose level is approximately 80 _ 1 OO mg / d I, which is said to be slightly higher after meals.
  • the metabolic promoter composition refers to the blood glucose level in vivo. A substance that promotes ascent.
  • fat burning mainly refers to a body fat burning action that burns fat stored in the body, but also includes an action of suppressing fat accumulation by inhibiting fat absorption in the body. It is a waste.
  • theanine promotes the utilization of lipids in the living body, thereby obtaining body fat burning action and fat accumulation inhibiting action.
  • anti-fatigue refers to occurrence of physical fatigue, recovery of physical fatigue, and maintenance / improvement of endurance.
  • theanine promotes utilization of lipids and carbohydrates in the living body, and thus has anti-fatigue action, fatigue recovery action, endurance maintenance action, endurance improvement action, nourishing tonic The effect is obtained
  • the metabolism promoting composition of the present invention can be provided as a pharmaceutical and a quasi-drug.
  • the active ingredient can be prepared by dissolving it in purified water or physiological saline as it is.
  • a quasi-drug it is preferably provided in a form that is easy to ingest as much as possible, such as a drinking form such as a container-packed drink, or a form such as a tablet, force capsule, or granule.
  • the metabolism promoting composition of the present invention can also be added to food and drink materials.
  • food and drink are intended for beverages and foods.
  • Such foods and drinks can be provided as health foods, health drinks, foods for specified health use, functional foods. In that case, it can be prepared by adding the metabolism-promoting composition of the present invention to food materials that are usually blended to produce each food and drink. In addition, when approved as food for specified health use, etc., these foods and drinks shall contain a label indicating that they contain theanine and are used to promote metabolism. It can also be sold as a fresh food or beverage.
  • the active ingredient of the present invention may be a variety of food materials (including fruits and jelly), milk ingredients, carbonic acid, excipients (including granulating agents), diluents, or even sweeteners, flavors,
  • food materials including fruits and jelly
  • milk ingredients including carbonic acid
  • excipients including granulating agents
  • diluents or even sweeteners, flavors
  • proteins such as wheat flour, starch, sugar, fats and oils, carbohydrate raw materials, vitamins, minerals, other physiologically active ingredients, hormones, nutritional ingredients, sports drinks, fruits Beverages, tea beverages, vegetable drinks, milk beverages, alcoholic beverages, jelly beverages, carbonated beverages and other beverages, jelly, chewing gum, chocolate, ice cream, candy, biscuits and other sweets, snacks, bread, cakes, etc.
  • Starch-based processed foods, fish paste products, livestock meat products, tofu, cheese and other protein-based processed foods, miso soy sauce, dore Seasonings such as single, other supplements, fodder, can be provided in the form of various food such as Bae Ttofu one de.
  • the amount of theanine in the composition and food and drink is not particularly limited as long as it does not impair the intended effect of the present invention.
  • 0.5 mg to 5 mg of theanine per 1 kg of the body weight of the administration subject Preferably, 0.5 mg to 2 mg of theanine is administered per kg of the subject's body weight.
  • the composition of the present invention is administered to an adult and the body weight is 40 kg to 1 OO kg, it is preferable to administer 2 Omg to 50 Omg of theanine, and 20 mg to 20 Omg. More preferably, theanine is administered.
  • theanine content when it is taken as a guide for a person weighing 60 kg, it is preferable to adjust the theanine content to 3 mg to 300 Omg, and in particular, to adjust the theanine content to 3 mg to 12 Omg. Further preferred.
  • Example 1 Theanine promotes lipid utilization
  • male mouse CDF 1 (10 weeks old, 20 animals) was used.
  • Theanine was prepared by dissolving L-theanine in pure water to prepare a theanine solution.
  • the mouse was exercised for 180 minutes in a rotating basket, exercised on the mouse, rested for 5 minutes, and then 0.5 mg / kg of theanine was applied. After intraperitoneal administration, the patient was rested for 30 minutes after administration, and then spontaneously exercised again in a rotating basket for 180 minutes.
  • mice were spontaneously operated in a rotating basket for 180 minutes and subjected to exercise load on the mice, then rested for 5 minutes and then administered intraperitoneally. He rested for 30 minutes, and then moved again for 80 minutes in a rotating basket.
  • Example 2 Theanine's action to reduce body fatigue ⁇ Endurance improving action Male mice CD F 1 (6 weeks old, 4 animals) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare a theanine solution with a theanine concentration of 0.05 mg / m I, and this was used as a sample.
  • theanine administration group (4 animals), after exercising for 80 minutes in a rotating basket and applying exercise to the mouse, resting for 5 minutes and then orally administering theanine 0.5 mg / kg. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes.
  • mice were exercised for 180 minutes in a rotating basket and subjected to exercise load, and then rested for 5 minutes, and then pure water 1 Om I / kg was orally administered. After administration, the patient was allowed to rest for 30 minutes, and then again exercised again for 180 minutes in a rotating basket.
  • mice CD F 1 Male mice CD F 1 (7 weeks old, 7 mice) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.02 mg / ml, 0.05 mg I, 0.15 mg / ml and used as samples.
  • a self-exercising exercise was performed with a rolling basket, and exercise load was applied. After resting for 5 minutes, water was administered orally. After the administration, the patient was rested for 30 minutes, and then spontaneously exercised again in a rotating basket for 180 minutes. The number of rotations of the rotating cage during the first exercise and the number of rotations of the second time were measured.
  • the control group received water.
  • Theanine dose is about 3 at a common ratio of 0.
  • Fig. 4 shows a graph showing the number of rotation reductions for each administration group as the number of rotation reductions (times).
  • the endurance improvement effect of theanine was investigated by forced swimming test. Male mice CDF 1 (6 weeks old, 8 animals) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions having theanine concentrations of 0.02 mg / ml, 0.05 mg / ml, and 0.15 mg / ml, and used as samples.
  • mice 8 animals in each group were used, and each mouse was fasted overnight (about 15 hours), then theanine or water was administered, and then left still for 60 minutes after After that, the test was performed using the same protocol as the above selection test, and the swimming time was measured.
  • the results are shown in FIG.
  • the doses of theanine were 0 • 2 mg / kg, 0.5 mg / kg, and 1.5 mg / kg at a common ratio of about 3.
  • Table 1 shows the initial values for each treatment group.
  • mice CD F 1 Male mice CD F 1 (6 weeks old, 5 mice) were used in the experiment.
  • L-theanine was dissolved in pure water to prepare theanine solutions with theanine concentrations of 0.05 mg / ml, 0.5 mg / ml, and 5. Omg / ml, and used as samples.
  • Test drink drinkl (placebo).
  • FIG. 9 shows AT values measured after ingestion of each test beverage for one week.
  • theanine low-dose and high-dose intake groups an increase in AT value was observed, and the exercise intensity that can be achieved by aerobic exercise increased.
  • FIG. 10 shows the blood lactate level (Delda value) before and after the multi-stage exercise test. Blood lactate levels at low and high theanine doses decreased. In recent years, it has been reported that lactic acid is an important cause of fatigue, so the decrease in lactic acid levels observed in the examples is thought to be the result of lactic acid contributing to recovery from fatigue.
  • Wistar male rats (Shizuoka experimental animals) were purchased at 7 weeks of age (approximately 250 g), preliminarily raised for one week, and then subjected to experiments.
  • the animal house is managed in a breeding room with a room temperature of 24 ⁇ 0.5 ° C, humidity of 55 ⁇ 5%, and a light / dark cycle (between 7:00 and 19:00).
  • Water and food (MF, manufactured by Oriental Yeast Co., Ltd.) ).
  • the osmotic pump (Alzet) which was fixed in the skull with dental cement and embedded in the back of the back, was inserted into the hippocampus on both sides.
  • Theanine manufactured by ITO EN was dissolved in physiological saline, filtered through a Millipore filter (Millex-GS, manufactured by Millipore), and then filled into an osmotic pump.
  • the drug concentrations were 0.1 u M 1 M and 10; UM, and physiological saline was administered as a control group.
  • the rat hippocampus was started with local theanine administration and fasted for about 36 hours from day 9. Thereafter, blood obtained by blood collection was used for analysis.
  • the blood sugar level at the time of slaughter was measured by the Medice Freeder (GR-101, TERUMO) equipped with a Medisafe chip (MS-FG25, TERUMO Co.).
  • Fig. 11 shows the results of examining the amount of growth hormone secreted in plasma
  • Fig. 12 shows the results of examining the amount of blood glucose produced.
  • Fig. 1 is a graph comparing the control exercise group (DW) and the theanine administration group (theanine) regarding the relative momentum in the lipid utilization promotion test of theanine (Example 1).
  • FIG. 2 is a graph comparing the control fatty acid group (DW) and the theanine administration group (theanine) with respect to blood fatty acid concentration in the lipid utilization promotion test for theanine (Example 1).
  • FIG. 3 Reduction of the physical fatigue of theanine ⁇
  • the number of rotation reduction (times) is a graph comparing the control administration group (water administration group) and the theanine administration group. is there.
  • FIG. 4 is a graph showing the number of reductions in rotations (times) for each administration group in the effective concentration confirmation test for theanine (Example 3).
  • FIG. 5 is a graph showing swimming time (seconds) for each administration group in the endurance improvement test (Example 4) of theanine.
  • FIG. 6 is a diagram showing an outline of an experimental procedure in the body fatigue reducing action (Example 5) of theanine.
  • FIG. 7 is a graph showing the amount of spontaneous exercise (times) for each administration group in the body fatigue alleviating action (Example 5) of theanine.
  • FIG. 9 is a diagram showing AT values measured after intake of each test beverage for one week. The AT values measured after ingestion of each test drink for 1 week are shown. An increase in AT was observed in the low and high dose theanine groups, and the exercise intensity that can be achieved with aerobic exercise increased.
  • FIG. 10 is a graph showing changes in blood lactic acid levels by a multi-stage exercise load test.
  • a treadmill was used for the exercise load.
  • a multi-stage exercise load test was conducted with a rotational speed of 0.5 km / h and a slope of 0%, and the rotational speed was increased by 0.5 km / h and the slope by 0.5% every 30 seconds. .
  • FIG. 1 1 is a diagram showing the results of examining the amount of growth hormone secreted in plasma.
  • FIG. 12 is a view showing the results of examining the secretion amount of blood glucose level.

Abstract

La présente invention concerne une composition destinée à stimuler le métabolisme, comprenant de la théine comme principe actif. La présente invention concerne également une boisson / un aliment comprenant la composition. La théine présente des effets stimulants sur le métabolisme, à savoir l'augmentation de l'utilisation des lipides, la stimulation de la sécrétion d'une hormone de croissance, l'augmentation du taux de glycémie, la combustion de graisses, l'atténuation de la fatigue lors d'exercices aérobies, l'augmentation du seuil anaérobie et la diminution de l'accumulation de lactates dans le sang.
PCT/JP2007/000804 2006-07-28 2007-07-27 Composition permettant de stimuler le métabolisme WO2008012952A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2006-205967 2006-07-28
JP2006205967A JP2008031080A (ja) 2006-07-28 2006-07-28 脂質利用促進組成物
JP2006-253686 2006-09-20
JP2006253686A JP2008074733A (ja) 2006-09-20 2006-09-20 持久力向上用組成物
JP2006287105A JP4709120B2 (ja) 2006-10-23 2006-10-23 成長ホルモン分泌促進用組成物
JP2006-287105 2006-10-23

Publications (1)

Publication Number Publication Date
WO2008012952A1 true WO2008012952A1 (fr) 2008-01-31

Family

ID=38981268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/000804 WO2008012952A1 (fr) 2006-07-28 2007-07-27 Composition permettant de stimuler le métabolisme

Country Status (1)

Country Link
WO (1) WO2008012952A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100230A (ja) * 1995-10-03 1997-04-15 Itouen:Kk 興奮促進剤
JP2001187736A (ja) * 1999-10-20 2001-07-10 Ito En Ltd 滋養強壮剤及び滋養強壮飲食物
JP2001316256A (ja) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd 血流改善用組成物
JP2002370979A (ja) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd 精神集中向上用組成物
WO2004093865A1 (fr) * 2003-04-24 2004-11-04 Amorepacific Corporation Composition pour maigrir
WO2005107734A1 (fr) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Composition accélérant le métabolisme de l'alcool et aliment ou boisson contenant la composition
JP2006077027A (ja) * 1999-10-20 2006-03-23 Ito En Ltd 滋養強壮剤及び滋養強壮飲食物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09100230A (ja) * 1995-10-03 1997-04-15 Itouen:Kk 興奮促進剤
JP2001187736A (ja) * 1999-10-20 2001-07-10 Ito En Ltd 滋養強壮剤及び滋養強壮飲食物
JP2006077027A (ja) * 1999-10-20 2006-03-23 Ito En Ltd 滋養強壮剤及び滋養強壮飲食物
JP2001316256A (ja) * 2000-04-28 2001-11-13 Taiyo Kagaku Co Ltd 血流改善用組成物
JP2002370979A (ja) * 2001-06-11 2002-12-24 Taiyo Kagaku Co Ltd 精神集中向上用組成物
WO2004093865A1 (fr) * 2003-04-24 2004-11-04 Amorepacific Corporation Composition pour maigrir
WO2005107734A1 (fr) * 2004-05-06 2005-11-17 Taiyokagaku Co., Ltd. Composition accélérant le métabolisme de l'alcool et aliment ou boisson contenant la composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945655B2 (en) 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions

Similar Documents

Publication Publication Date Title
JP3907964B2 (ja) 精神疲労軽減組成物、集中力維持増強組成物及び精神的活力維持増強組成物
EP2050444A1 (fr) Agent de réduction de la fatigue
WO2001087291A1 (fr) Compositions permettant de regulariser le rythme circadien
EP2532351B1 (fr) Agent pour améliorer la motilité
CN104922115A (zh) 含有氨基酸组合物的抗疲劳剂
EP3115047B1 (fr) Agent prévenant la débilité
KR100481379B1 (ko) 체지방률을낮추고체조성을개선시키는식품조성물및체지방률을낮추고체조성을개선시키는방법
CN102273581A (zh) 一种高甜度复配甜味剂
JP3433917B2 (ja) 体タンパク質蓄積効率を亢進する栄養組成物
JP2005213185A (ja) エネルギー補給および抗疲労飲食品
JP5394644B2 (ja) アスペルロシドまたはその類縁体を含む筋肉増強剤
WO2008012952A1 (fr) Composition permettant de stimuler le métabolisme
JP4163801B2 (ja) アルコール代謝促進作用物
JP2008031080A (ja) 脂質利用促進組成物
CA2757351C (fr) Agent anti-fatigue mentale
TW200812569A (en) Bone density increasing agent
JP2001048794A (ja) 桑の葉由来粉末およびカキ由来粉末の混合物を含むｎｉｄｄｍ治療用の医薬組成物および健康食品
JP6881984B2 (ja) 過食抑制剤
JP4709120B2 (ja) 成長ホルモン分泌促進用組成物
JP2012180331A (ja) 筋損傷の早期回復の誘導用の経口摂取剤
US20230025468A1 (en) Method and a dietary composition on regulation, treatment, and prevention of obesity
JP2000302677A (ja) カルニチン自己産生能改善作用を有する医薬および食品・飼料組成物
JP2008074733A (ja) 持久力向上用組成物
JP2021016375A (ja) 有酸素性運動機能向上剤、有酸素性運動機能向上用食品組成物、有酸素性運動機能向上用医薬組成物
JP2023160181A (ja) オルニチン血中濃度向上剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07790298

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07790298

Country of ref document: EP

Kind code of ref document: A1